GENE ONLINE|News &
Opinion
Blog

2021-07-16| ChinaIPO

China’s Brii Bio Raises $319 million in the Hong Kong IPO

by Tyler Chen
Share To

China’s Brii Biosciences has raised $319 million in the initial public offering (IPO) in HKEX. The company announced that the proceeds would be used to support the development of its infectious diseases pipeline, including HBV, HIV, and COVID-19 therapies.

The firm released around 111 million shares on July 13th at HK$22.25 per share, and the cornerstone investors have agreed to acquire 47.52% of them.

“Listing on the Hong Kong Stock Exchange marks an important milestone for our company,” Brii Bio’s CEO Zhi Hong pointed out, “By leveraging our remarkable senior management as well as our experience of conducting multi-regional clinical trials, we will continue to expand our pipeline through our in-house R&D efforts, and in-licenses or collaborations on appropriate drug candidates.”

Brii Bio’s main focus is to deliver innovative solutions to treating infectious diseases and central nervous system (CNS) diseases. Their star pipeline included treatments for HBV, HIV, multidrug-resistant (MDR), extensive drug-resistant (XDR) gram-negative infections, and COVID-19.

Currently, the COVID-19 antibodies BRII-196 and BRII-198 are the most advanced in clinical trials. Both of them have entered phase 3 clinical trials. On the other hand, HBV therapies BRII-179 (immuno-therapy), BRII-835 (siRNA), and the combination therapies come next, entering Phase 2 clinical trials while HIV treatments are in Phase 1 trials.

As for CNS therapies, BRII-296 is tested for two indications: a Phase 1 clinical trial targeting postpartum depression (PPD) and the other in the preclinical stage addressing major depressive disorder (MDD).

On March 23rd, Brii Bio finished the Series C financing, scoring $155 million to boost its current pipeline.

Related Article: Chinese Oncology Drugmaker to Raise over 600 Million in Hong Kong IPO

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
Pioneering Partnership: Africa CDC and China CDC Elevate Public Health Initiatives
2023-11-20
Biotheus Collaborates with BioNTech for Global Development of Cancer Therapy
2023-11-08
LATEST
Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
2024-02-23
Revolutionary AI-Powered Respiratory Monitor Maker Gets Financial Boost with Latest Funding
2024-02-21
Researchers Predict Drug Interactions with Machine Learning to Enhance Patient Safety
2024-02-21
USC-Led Study Reveals Benefits of Fasting-Mimicking Diet in Reducing Disease Risk and Slowing Aging
2024-02-21
Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro
2024-02-21
Targeted Cancer Therapy Breakthrough: Degrader-Antibody Conjugates (DACs) Advance to Clinical Trials
2024-02-19
Degrader-Antibody Conjugates (DACs): Targeted Degradation for Therapeutics
2024-02-19
EVENT
Scroll to Top